In the News: Generic Xeloda Approved
You might have seen in the news: this week, the FDA approved the first generic version of capecitabine (Xeloda to most of us), an oral chemotherapy pill used to treat breast and colon cancers.
So what does this mean? Basically, when generic versions of drugs become available to the masses, it can mean better access for patients. We all know – brand-name drugs can be VERY pricey, sometimes so much so that people who need the drug can’t even afford it. The good news: typically, generic forms of drugs cost significantly less than the brand-name equivalents and still provide the same effectiveness.
So in this case, patients who had been receiving the brand-name version of Xeloda will be spending less for the same treatment and patients who couldn’t afford the medication can now ask their doctors if the generic version is right for them.
Different Drug, Same Quality
If you’re worried about the quality of these new, non-name-brand forms of Xeloda, don’t be. Remember that all FDA-approved generic drugs are subject to the same stringent guidelines and are held to the same standards as their brand-name equivalent. Actually, as cancer continues to be treated as a chronic illness, we will likely be seeing other generic versions of popular treatments become available. A generic drug may look or taste different or even have different inactive ingredients, but in general, it shouldn’t be any less effective for you.
Ow, Ow! Choose Me! Over Here!
So then why are generic drugs SO much cheaper? Because the companies that offer these drugs didn’t have to spend the money to research, develop and market them (and as you can imagine – this process this isn’t a cheap one.) Another reason: more forms of a drug on the market means increased competition; companies are forced to keep their prices lower so that people will actually buy their product.
There you have it! If you have questions, call our Toll-free Helpline at (877) 422-2030. Find more information here.
Top resources

Where breakthroughs begin: Project Cure CRC spotlight on Dr. Lisa Mielke
hrough Project Cure CRC, the Alliance is fueling bold, early-stage research with the potential to transform colorectal cancer treatment. Dr. Lisa Mielke’s groundbreaking work explores how the gut’s immune system and nerve signaling influence cancer growth—opening the door to new therapeutic approaches, including repurposed existing drugs. This is what’s possible when promising ideas get the support they need to move forward.

John E.: Biomarker testing uncovered a pivotal treatment option
After a grim prognosis, biomarker testing revealed a targeted treatment option for John E. Learn how knowing your biomarkers can change what’s possible.

"Clinical trials gave us time": A daughter’s tribute to her mother’s courage
When Kate Shin’s mother faced rectal cancer, clinical trials gave them precious time together. Now, Kate shares her story to encourage access to screening and innovative care, including clinical trials.




